SecBot SecBot
144 ·Filed Aug 11, 2026

FTH

Faeth Therapeutics, Inc.
BEARISH
Impact 5/10
Horizondays Processed3mo ago SEC0001959173-26-005879
Form 144, notice of proposed sale of securities
Actionable Insight ▼ Bearish

Monitor for actual execution of this sale on Form 4 filings. A large insider sale by a 10% holder could signal reduced conviction, but the stock has strong analyst consensus (93% bullish) and a history of positive post-report drift. Watch for any subsequent Form 4 filings to confirm the sale.

DirectionBearish
Confidencemedium
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$30.00
T+0 close · Aug 11, 2026 · via day close
Latest settled
−35.00%
T+60 · $19.50
Vs SPY
−34.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $30.00entry
  2. T+1 · 3mo ago −2.07%α −2.32% · $29.38
  3. T+5 · 3mo ago +10.00%α +10.40% · $33.00
  4. T+20 · 2mo ago +20.40%α +21.46% · $36.12
  5. T+60 · 13d ago −35.00%α −34.86% · $19.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cambrian BioPharma Inc, a 10% stockholder of Faeth Therapeutics, filed a Form 144 notice of intent to sell 130,142 shares of common stock, with an estimated aggregate market value of approximately $3.64 million. The shares were acquired in a private placement in January 2020. This represents a notable insider selling signal from a major shareholder, though the sale is not yet executed and the filing is an advance notice of intent.

Key Facts

  • Cambrian BioPharma Inc, a 10% stockholder, filed a Form 144 to sell 130,142 shares of Faeth Therapeutics common stock.
  • The estimated aggregate market value of the proposed sale is approximately $3.64 million based on a 07/22/2026 trade date.
  • Shares were acquired in a private placement on 01/10/2020.
  • The filing date is 08/11/2026, and the sale is planned through Fidelity Brokerage Services LLC.

Financial Impact

Proposed sale of 130,142 shares valued at approximately $3.64 million, representing about 0.5% of the company's $738M market cap.

dilutioninsider selling

Risk Factors

  • Insider selling by a major shareholder may indicate reduced confidence in near-term prospects.
  • The sale is not yet executed; the filing only signals intent, and the insider may not follow through.

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-005879
Document: 0001959173-26-005879-index.html0001959173-26-005879
Document: 0001959173-26-005879.txt0001959173-26-005879

US Market Status

Market Closed · Opens Wed (13h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 11, 2026